Heron Therapeutics misses Q2 earnings and revenue estimates, pauses sales expansion, withdraws full-year outlook.

Heron Therapeutics reported a Q2 loss per share of -$0.03, missing analyst expectations of -$0.02, with revenue of $37.67 million falling short of the $42.19 million estimate. Despite 44% growth in its acute-care franchise, slower expansion of key products and increased competition led to weaker sales. The company paused its planned salesforce expansion and withdrew its full-year financial outlook amid these challenges. Heron remains unprofitable with elevated financial risk due to high debt levels.